Fund Details
Overview
Investment portfolio
16rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
OTR Therapeutics | Dec 2025Participated | $100 MSeries A | |
Kailera Therapeutics | Oct 2025Participated | $600 MSeries B | |
Synnovation Therapeutics | Jan 2024Participated | $102 MSeries A | |
ArriVent Biopharma | Mar 2023Participated | $155 MSeries B | |
ADARx Pharmaceuticals | Jan 2023Participated | $46 MSeries B | |
CG Oncology | Nov 2022Participated | $120 MSeries E | |
Fuse Biotherapeutics | Nov 2021Participated | $10 MSeed | |
Antiva Biosciences | Nov 2021Participated | $31 MSeries D | |
ADARx Pharmaceuticals | Sep 2021Participated | $75 MSeries B | |
Antiva Biosciences | Jul 2018Participated | $15 MSeries C | |
Constellation Pharmaceuticals | Apr 2018Participated | $100 MOther Equity | |
Arvinas | Apr 2018Participated | $55 MSeries C | |
OTR Therapeutics | Dec 2025Participated | $100 MSeries A | |
Kailera Therapeutics | Oct 2025Participated | $600 MSeries B | |
Synnovation Therapeutics | Jan 2024Participated | $102 MSeries A | |
ArriVent Biopharma | Mar 2023Participated | $155 MSeries B | |
ADARx Pharmaceuticals | Jan 2023Participated | $46 MSeries B | |
CG Oncology | Nov 2022Participated | $120 MSeries E | |
Fuse Biotherapeutics | Nov 2021Participated | $10 MSeed | |
Antiva Biosciences | Nov 2021Participated | $31 MSeries D | |
ADARx Pharmaceuticals | Sep 2021Participated | $75 MSeries B | |
Antiva Biosciences | Jul 2018Participated | $15 MSeries C | |
Constellation Pharmaceuticals | Apr 2018Participated | $100 MOther Equity | |
Arvinas | Apr 2018Participated | $55 MSeries C |
16 Items
16
Items
...
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 0 | 1 |
| Series A | 0 | 3 |
| Series B | 0 | 5 |
| Series C+ | 0 | 6 |
| Other Equity | 0 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Nov '17 | 1 |
| Dec '17 | 1 |
| Jan '18 | 0 |
| Feb '18 | 1 |
| Mar '18 | 1 |
| Apr '18 | 2 |
| May '18 | 0 |
| Jun '18 | 0 |
| Jul '18 | 1 |
| Aug '18 | 0 |
| Sep '18 | 0 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 1 |
| Oct '21 | 0 |
| Nov '21 | 2 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 1 |
| Dec '22 | 0 |
| Jan '23 | 1 |
| Feb '23 | 0 |
| Mar '23 | 1 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 1 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 1 |
| Nov '25 | 0 |
| Dec '25 | 1 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 16 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 1 |
| $10M-$25M | 1 |
| $25M-$50M | 2 |
| $50M-$100M | 4 |
| $100M-$250M | 6 |
| $250M-$500M | 1 |
| $500M-$1B | 1 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 15 |
| China | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Lilly Asia Ventures | 5 |
| OrbiMed | 5 |
| Hillhouse Capital | 4 |
| Alexandria Venture Investments | 3 |
| Canaan Partners | 3 |
| Sofinnova Ventures | 3 |
| SR One | 3 |
| 6 Dimensions Capital | 2 |
| Brace Pharma Capital | 2 |
| Casdin Capital | 2 |
| Cormorant Asset Management | 2 |
| Deerfield Management | 2 |
| Fidelity Management & Research Company | 2 |
| HBM Healthcare Investments | 2 |
| Hillhouse Capital Group | 2 |
| Lumira Ventures | 2 |
| Osage University Partners | 2 |
| Qatar Investment Authority | 2 |
| RA Capital Management | 2 |
| Third Rock Ventures | 2 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 0 | 0% |
| Participating | 16 | 100% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 0 | 0% |
| Co-led | 0 | 0% |
Lead dynamics requires at least one led deal in this range
Team
Ethan Zhao
Partner
Sirona Capital
Founder